Last reviewed · How we verify

NCT03385798: EGIAES

Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy

Completed NA Last updated 31 May 2023
What this trial tests

NA trial testing Endowrist in Bladder Cancer in 90 participants. Completed in 1 January 2023.

Timeline
1 January 2018
Primary endpoint
1 January 2020
1 January 2023

Quick facts

Lead sponsorJørgen Bjerggaard Jensen
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment90
Start date1 January 2018
Primary completion1 January 2020
Estimated completion1 January 2023
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Jørgen Bjerggaard Jensen — full company profile →

Who can join

18 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a randomized clinical trial (RCT) including patients undergoing robotic assisted cystectomy with intracorporeal ileal conduit at four large university hospitals in Denmark. If included, the patients will be randomized 1:1 to two study arms: 1) Standard arm with current procedure where intracorporeal bowel anastomosis is performed with the 60 mm EndoGIA stapler, or 2) Experimental arm where the bowel anastomosis will be performed totally robotic with the Endowrist Intuitive robotic stapler with 2 subsequent elongated 45 mm magazines for the side-to-side anastomosis. Primary outcome will be postoperative bowel function where a better bowel recovery is anticipated in the experimental Endowrist arm whereas serious complications are expected to be non-inferior to the current standard.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Comparison of the EndoGIA versus the Endowrist stapler in intracorporeal urinary diversion in robotic assisted radical cystectomy (EGIAES) - a randomized multicentre trial.
    Bak R, Fabrin K, Jensen TK, Olsen KØ, et al · · 2025 · PMID 41335393 · DOI 10.1007/s11701-025-03009-6

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

Other Jørgen Bjerggaard Jensen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03385798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing